NASDAQ:OLMA Olema Pharmaceuticals (OLMA) Stock Forecast, Price & News $6.31 +0.36 (+6.05%) (As of 06/6/2023 ET) Add Compare Share Share Today's Range$5.72▼$6.4250-Day Range$3.22▼$7.2752-Week Range$2.19▼$7.45Volume140,921 shsAverage Volume178,051 shsMarket Capitalization$257.20 millionP/E RatioN/ADividend YieldN/APrice Target$15.25 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Olema Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside141.7% Upside$15.25 Price TargetShort InterestBearish2.97% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.79) to ($2.92) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.06 out of 5 starsMedical Sector512th out of 981 stocksPharmaceutical Preparations Industry239th out of 459 stocks 3.5 Analyst's Opinion Consensus RatingOlema Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.25, Olema Pharmaceuticals has a forecasted upside of 141.7% from its current price of $6.31.Amount of Analyst CoverageOlema Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.97% of the float of Olema Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverOlema Pharmaceuticals has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Olema Pharmaceuticals has recently increased by 0.98%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldOlema Pharmaceuticals does not currently pay a dividend.Dividend GrowthOlema Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OLMA. Previous Next 2.7 News and Social Media Coverage News SentimentOlema Pharmaceuticals has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.Search InterestOnly 1 people have searched for OLMA on MarketBeat in the last 30 days. This is a decrease of -94% compared to the previous 30 days.MarketBeat Follows2 people have added Olema Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Olema Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders23.50% of the stock of Olema Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.41% of the stock of Olema Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Olema Pharmaceuticals are expected to decrease in the coming year, from ($2.79) to ($2.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Olema Pharmaceuticals is -2.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Olema Pharmaceuticals is -2.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOlema Pharmaceuticals has a P/B Ratio of 1.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Olema Pharmaceuticals (NASDAQ:OLMA) StockOlema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.Read More Receive OLMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Olema Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address OLMA Stock News HeadlinesMay 30, 2023 | finance.yahoo.comOlema Oncology to Present at the 2023 Jefferies Healthcare ConferenceMay 19, 2023 | finance.yahoo.comInstitutional investors own a significant stake of 42% in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)June 7, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!May 16, 2023 | americanbankingnews.comQ3 2023 Earnings Estimate for Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Issued By Capital One FinancialMay 13, 2023 | americanbankingnews.comCapital One Financial Raises Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $20.00May 11, 2023 | msn.comHC Wainwright & Co. Maintains Olema Pharmaceuticals (OLMA) Buy RecommendationMay 11, 2023 | finance.yahoo.comOlema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 StudyMay 10, 2023 | americanbankingnews.comHC Wainwright Lowers Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $14.00June 7, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 9, 2023 | finance.yahoo.comOlema Oncology Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 8, 2023 | finance.yahoo.comOlema Oncology Announces Upcoming Poster Presentation at the 2023 ESMO Breast Cancer Annual CongressMay 6, 2023 | americanbankingnews.comOlema Pharmaceuticals (NASDAQ:OLMA) Now Covered by Analysts at Capital One FinancialMay 5, 2023 | americanbankingnews.comOlema Pharmaceuticals (NASDAQ:OLMA) Coverage Initiated at Capital One FinancialMay 2, 2023 | americanbankingnews.comLifesci Capital Weighs in on Olema Pharmaceuticals, Inc.'s FY2023 Earnings (NASDAQ:OLMA)April 29, 2023 | americanbankingnews.comOlema Pharmaceuticals (NASDAQ:OLMA) Receives "Outperform" Rating from Lifesci CapitalApril 29, 2023 | americanbankingnews.comOlema Pharmaceuticals (NASDAQ:OLMA) Rating Reiterated by Lifesci CapitalApril 29, 2023 | americanbankingnews.comLifesci Capital Reiterates "Outperform" Rating for Olema Pharmaceuticals (NASDAQ:OLMA)April 13, 2023 | finance.yahoo.comOlema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual ConferenceMarch 11, 2023 | marketwatch.comOlema Pharmaceuticals to Reduce Workforce by 25% Amid Broader RestructuringMarch 11, 2023 | seekingalpha.comOlema Pharmaceuticals GAAP EPS of -$0.65 in-lineMarch 10, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: aTyr Pharma (LIFE), COMPASS Pathways (CMPS) and Olema Pharmaceuticals (OLMA)March 9, 2023 | seekingalpha.comOLMAMarch 9, 2023 | finance.yahoo.comOlema Oncology Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Strategic UpdateMarch 2, 2023 | benzinga.comOlema Oncology to Present at Oppenheimer 33rd Annual Healthcare ConferenceFebruary 21, 2023 | finance.yahoo.comOlema Oncology to Participate at Upcoming Investor ConferencesJanuary 2, 2023 | finance.yahoo.comWe Think Olema Pharmaceuticals (NASDAQ:OLMA) Needs To Drive Business Growth CarefullyDecember 7, 2022 | finance.yahoo.comOlema Oncology Announces OP-1250 Demonstrates Attractive Combinability with CDK 4/6 Inhibitor Palbociclib in Phase 1b Dose Escalation StudySee More Headlines OLMA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OLMA Company Calendar Last Earnings3/09/2023Today6/06/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OLMA CUSIPN/A CIK1750284 Webwww.olema.com Phone650-243-5555FaxN/AEmployees73Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.25 High Stock Price Forecast$20.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+142.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-104,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-53.26% Return on Assets-49.24% Debt Debt-to-Equity RatioN/A Current Ratio9.76 Quick Ratio9.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.90 per share Price / Book1.28Miscellaneous Outstanding Shares40,760,000Free Float31,183,000Market Cap$256.38 million OptionableNot Optionable Beta2.32 Key ExecutivesDr. Sean P. Bohen M.D. (Age 56)Ph.D., Pres, CEO & Director Comp: $999.3kMr. Shane William Charles Kovacs M.B.A. (Age 49)Chief Operating & Financial Officer Comp: $875.55kDr. Cyrus L. Harmon Ph.D. (Age 52)Chief Research Officer & Director Mr. Kinney Horn (Age 49)Chief Bus. Officer Comp: $588.3kDr. Peter J. Kushner Ph.D. (Age 84)Co-Founder & Sr. Research Fellow Ms. Courtney DuganVP of Investor Relations & CommunicationsMr. John B. Moriarty Jr. (Age 55)Exec. VP, Chief Legal Officer & Corp. Sec. Ms. Julie DexterVP & Head of PeopleDr. David C. Myles Ph.D. (Age 60)Chief Discovery & Non-Clinical Devel. Officer Ms. Demiana Faltaos Ph.D.Pharm.D., VP & Head of Clinical PharmacologyMore ExecutivesKey CompetitorsUroGen PharmaNASDAQ:URGNKamadaNASDAQ:KMDAVerrica PharmaceuticalsNASDAQ:VRCACorMedixNASDAQ:CRMDVaxxinityNASDAQ:VAXXView All CompetitorsInsiders & InstitutionsEP Wealth Advisors LLCBought 4,508 shares on 6/5/2023Ownership: 0.011%Prelude Capital Management LLCSold 3,726 shares on 6/1/2023Ownership: 0.040%Geode Capital Management LLCBought 13,047 shares on 5/16/2023Ownership: 0.860%State Street CorpBought 12,100 shares on 5/16/2023Ownership: 0.298%Squarepoint Ops LLCBought 23,943 shares on 5/16/2023Ownership: 0.059%View All Insider TransactionsView All Institutional Transactions OLMA Stock - Frequently Asked Questions Should I buy or sell Olema Pharmaceuticals stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Olema Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OLMA shares. View OLMA analyst ratings or view top-rated stocks. What is Olema Pharmaceuticals' stock price forecast for 2023? 5 brokers have issued 1-year price targets for Olema Pharmaceuticals' stock. Their OLMA share price forecasts range from $11.00 to $20.00. On average, they expect the company's stock price to reach $15.25 in the next twelve months. This suggests a possible upside of 142.4% from the stock's current price. View analysts price targets for OLMA or view top-rated stocks among Wall Street analysts. How have OLMA shares performed in 2023? Olema Pharmaceuticals' stock was trading at $2.45 at the beginning of the year. Since then, OLMA stock has increased by 156.7% and is now trading at $6.29. View the best growth stocks for 2023 here. When is Olema Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our OLMA earnings forecast. How were Olema Pharmaceuticals' earnings last quarter? Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) released its earnings results on Thursday, March, 9th. The company reported ($0.65) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.65). When did Olema Pharmaceuticals IPO? (OLMA) raised $170 million in an initial public offering on Thursday, November 19th 2020. The company issued 10,000,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies, Cowen and Canaccord Genuity served as the underwriters for the IPO. What is Olema Pharmaceuticals' stock symbol? Olema Pharmaceuticals trades on the NASDAQ under the ticker symbol "OLMA." Who are Olema Pharmaceuticals' major shareholders? Olema Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.45%), Sectoral Asset Management Inc. (2.45%), Geode Capital Management LLC (0.86%), Vontobel Holding Ltd. (0.83%), Renaissance Technologies LLC (0.63%) and Deutsche Bank AG (0.63%). Insiders that own company stock include Bvf Partners L P/Il, Cormorant Asset Management, Lp, Cyrus Harmon, G Walmsley Graham, Kinney Horn and Sean Bohen. View institutional ownership trends. How do I buy shares of Olema Pharmaceuticals? Shares of OLMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Olema Pharmaceuticals' stock price today? One share of OLMA stock can currently be purchased for approximately $6.29. How much money does Olema Pharmaceuticals make? Olema Pharmaceuticals (NASDAQ:OLMA) has a market capitalization of $256.38 million. The company earns $-104,790,000.00 in net income (profit) each year or ($2.74) on an earnings per share basis. How can I contact Olema Pharmaceuticals? Olema Pharmaceuticals' mailing address is 512 2ND STREET 4TH FLOOR, SAN FRANCISCO CA, 94107. The official website for the company is www.olema.com. The company can be reached via phone at 650-243-5555 or via email at ir@olema.com. This page (NASDAQ:OLMA) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Olema Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.